Concepedia

Publication | Open Access

Brentuximab Vedotin Plus AVD for First-Line Treatment of Early-Stage Unfavorable Hodgkin Lymphoma (BREACH): A Multicenter, Open-Label, Randomized, Phase II Trial

DOIFull Paper Access

65

Citations

28

References

2022

Year

Luc‐Matthieu Fornecker, Julien Lazarovici, Igor Aurer, Olivier Casasnovas, Anne‐Claire Gac, Christophe Bonnet, Krimo Bouabdallah, Pierre Feugier, Lena Specht, Lysiane Molina,
Journal of Clinical Oncology

Abstract

BV-AVD demonstrated an improvement in the PET-negative rate compared with ABVD after two cycles.

References

YearCitations

Page 1